Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFPT1 | Q06210 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | CASR | P41180 | 3/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.42 |
| ▸ | GGT1 | P19440 | 4/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25345631 | 1.00 | GFPT1 (0.52) | GFPT1SLC7A5CASRGRIK1PTGS1 | |
| SCHEMBL542281 | 1.00 | GFPT1 (0.52) | GFPT1SLC7A5CASRGRIK1PTGS1 | |
| SCHEMBL1768739 | 0.84 | CASR (0.45) | GFPT1SLC7A5CASR | |
| SCHEMBL1768743 | 0.84 | CASR (0.45) | GFPT1SLC7A5CASR | |
| SCHEMBL28387960 | 0.83 | KDM4E (0.39) | GFPT1CASR | |
| SCHEMBL10280376 | 0.82 | GFPT1 (0.49) | GFPT1SLC7A5CASRGRIK1PTGS1 | |
| SCHEMBL2716862 | 0.82 | GFPT1 (0.49) | GFPT1SLC7A5CASRGRIK1PTGS1 | |
| SCHEMBL14381155 | 0.81 | KDM4E (0.37) | GFPT1CASR | |
| SCHEMBL19371884 | 0.81 | KDM4E (0.37) | GFPT1CASR | |
| SCHEMBL31524073 | 0.80 | CYP2D6 (0.50) | GFPT1SLC7A5CASRGRIK1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9101662-B2 | Compositions with modulating agents | FOAMIX PHARMACEUTICALS LTD. (IL) | 2015-08-11 | — | — | US | claimed |
| US-8795693-B2 | Compositions with modulating agents | FOAMIX LTD. (IL) | 2014-08-05 | — | — | US | claimed |
| EP-2097065-A2 | FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS | Foamix Ltd. (IL) | 2009-09-09 | — | — | EP | claimed |
| WO-2008152444-A2 | FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS | FOAMIX LTD. (US) | 2008-12-18 | — | — | WO | claimed |
| EP-1976873-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Brystol-Myers Squibb Company (US) | 2008-10-08 | — | — | EP | claimed |
| US-20080206159-A1 | Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions | FOAMIX LTD. (IL) | 2008-08-28 | — | — | US | claimed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | claimed |
| WO-2007082264-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | claimed |
| US-12624067-B2 | Cyclic peptide, cell scaffold material, cell separating material, and medium | FUJIFILM CORPORATION (JP) | 2026-05-12 | — | — | US | disclosed |
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724459-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Peptidream Inc (JP) | 2026-04-15 | — | — | EP | disclosed |
| EP-4540267-B1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2024254339-A9 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| CN-113993882-B | Cyclic peptides, cell scaffold material, cell separation material and culture medium | 富士胶片株式会社 | 2024-12-17 | — | — | CN | disclosed |
| US-20070254315-A1 | SCREENING FOR NEUROTOXIC AMINO ACID ASSOCIATED WITH NEUROLOGICAL DISORDERS | THE INSTITUTE FOR ETHNOMEDICINE (US) | 2007-11-01 | — | — | US | disclosed |
| US-7256002-B2 | Screening for neurotoxic amino acid associated with neurological disorders | THE INSTITUTE FOR ETHNOMEDICINE (US) | 2007-08-14 | — | — | US | disclosed |
| EP-1664793-A1 | NEUROTOXIC AMINO ACID OR NEUROTOXIC DERIVATIVE THEREOF ASSOCIATED WITH NEUROLOGICAL DISORDERS | Institute For Ethnomedicine (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005019830-A1 | NEUROTOXIC AMINO ACID OR NEUROTOXIC DERIVATIVE THEREOF ASSOCIATED WITH NEUROLOGICAL DISORDERS | INSTITUTE FOR ETHNOMEDICINE (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050042686-A1 | Neurotoxic amino acid or neurotoxic derivative thereof associated with neurological disorders | NATIONAL TROPICAL BOTANICAL GARDEN | 2005-02-24 | — | — | US | disclosed |
| EP-0350163-A2 | Renin inhibitory peptides | BEECHAM GROUP PLC (GB) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | GLP1R, GIPR, IAPP | GFPT1 1805/4885SLC7A5 2674/4885CASR 803/4885 |
| US-20080206159-A1 | Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions | CUTA, SLTM, SMO | GFPT1 3155/4885SLC7A5 4410/4885CASR 2351/4885 |
| US-12624067-B2 | Cyclic peptide, cell scaffold material, cell separating material, and medium | ITGB1, ITGAM, ITGA1 | GFPT1 1001/4885SLC7A5 392/4885CASR 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.